Truist Financial Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,004

Futu News18minutes ago · Ratings

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

GlobeNewswire05:05

Regeneron Pharmaceuticals Analyst Ratings

Benzinga01:14 · Ratings

RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,184

Futu NewsJan 7 22:31 · Ratings

RBC Trims Price Target on Regeneron Pharmaceuticals to $1,184 From $1,215, Keeps Outperform Rating

MT NewswiresJan 7 20:21 · Ratings

Bernstein Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,070

Futu NewsJan 7 17:34 · Ratings